Image

Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing

Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing

Recruiting
2-65 years
All
Phase N/A

Powered by AI

Overview

Background

Vector-borne diseases are caused by the bite of an infected mosquito, fly, flea, tick, or other blood-feeder. These diseases cause almost 1 million deaths per year. And they are on the rise, particularly in Southeast Asia in particular. Researchers think that these diseases make up about 10 percent of fevers in Cambodia. But many of these illnesses are never diagnosed. Studying these diseases can help find new ways to identify and treat them.

Objective

To find pathogens in people who have a fever using metagenomic pathogen sequencing platforms.

Eligibility

People aged 2 months to 65 years with a fever of at least 38 degrees Celsius or those diagnosed with infection by a pathogen of concern who visit the referral hospital in Cambodia. Close contacts of people diagnosed with infection by a pathogen of concern may also be enrolled.

Design

Participants will be screened with their medical history. Children will be weighed to make sure they are big enough to give blood samples.

Participants will share data about their sex, age, and where they live. They will answer more questions about their heath history. They will answer questions about and any places to which they have recently traveled. They will take a questionnaire. They will have a blood test. If they have respiratory symptoms, they will have a nasal swab.

Participants may be contacted within 1-2 weeks (early) and/or within 3 months (late) from their enrollment date to provide an optional follow-up blood samples and nasal swabs.

Description

Vector-borne diseases continue to cause significant global morbidity and mortality, particularly in Southeast Asia. However, given a lack of diagnostics available in resource-poor countries, many vector-borne diseases are never diagnosed and therefore their impact is underappreciated. Cross-sectional retrospective surveys have revealed higher than expected antibody prevalence to a number of diseases including mosquito-borne viruses and ectoparasite-borne rickettsial diseases.

Here, we aim to collect specimens from individuals with acute febrile illness or red flag pathogens to better describe the febrile disease landscape of Cambodia using novel genomics technologies (unbiased next-generation sequencing) to investigate possible infectious etiologies of illnesses of unexplained etiology in Cambodian children and adults. If a highly transmissible and/or highly virulent (red flag) pathogen of public health concern is identified, we will take a convalescent sample from the individual and screen his/her close contacts with serological and molecular assays to add an additional layer of understanding of the disease burden. With the current rise of vector-borne diseases around the world, we hope the results of this study contribute to better understanding the epidemiology and burden for

vector-borne diseases in this region.

Eligibility

  • INCLUSION CRITERIA:
        In order to be eligible to participate in this study, an individual must meet all of the
        following criteria:
        Provision of signed and dated informed consent form.
        Stated willingness to comply with all study procedures.
        Male or female, aged 2 months to 65 years.
        Meets one of the following case definitions:
          -  Febrile patient: has documented fever equal to or greater than 38 degrees celsius in
             previous 24 hours.
          -  Red flag patient: is an individual with disease relating to a red flag pathogen (see
             list, below), with confirmed standard laboratory testing (e.g., blood culture,
             polymerase chain reaction [PCR]) for the pathogen in question.
          -  Afebrile close contact: is an afebrile individual who lived in the same household or
             worked in the same enclosed workspace on a daily basis with a red flag patient at the
             time they got sick with a known pathogen.
        Red Flag Pathogens:
          -  Yersinia pestis
          -  Corynebacterium diphtheriae
          -  Salmonella typhi
          -  Salmonella paratyphi
          -  Streptococcus suis
          -  Burkholderia cepacia or pseudomallei
          -  Avian influenza
          -  Swine influenza
          -  Betacoronaviruses
          -  Nipah virus
          -  Measles virus
          -  Chikungunya virus
          -  Zika virus
          -  SFTS virus (severe fever with thrombocytopenia syndrome)
        Willing to allow biological samples to be stored for future research and for all
        de-identified metagenomic sequencing data to be stored in publicly accessible databases.
        EXCLUSION CRITERIA:
        Any underlying, chronic, or current medical condition that, in the opinion of the
        investigator, would interfere with participation in the study (e.g., inability or great
        difficulty in drawing blood).
        Any febrile individual who has had surgery in the prior month.
        Any patient who enrolled and exited this study within 30 days of the initial study blood
        draw, or afebrile close contact who enrolled and exited within 14 days.

Study details
    Vector-Borne Diseases
    Emerging Pathogens

NCT04034264

National Institute of Allergy and Infectious Diseases (NIAID)

1 May 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.